A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-671)